Key result
Ticagrelor causes mild, transient dyspnea in ~15% of patients, rarely requiring drug discontinuation.
Why the study?
How should dyspnoea be managed in acute coronary syndrome patients treated with ticagrelor?
How should dyspnoea be managed in acute coronary syndrome patients treated with ticagrelor?
Ticagrelor-induced dyspnoea is a common but usually benign and transient side effect that rarely warrants switching to alternative P2Y12 inhibitors.
Supports reserving ticagrelor discontinuation for persistent intolerable dyspnoea in ACS; leaves open need for prospective trials on management thresholds.
The occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet receptor inhibitors (i.e., clopidogrel, prasugrel and ticagrelor) are currently the cornerstone of treatment of ACS patients. Thus, in the last few years, the potential association between ACS and dyspnoea has also become more challenging with the increasing use of ticagrelor in these patients due to its beneficial effects on ischaemic event prevention and mortality, since ticagrelor can induce dyspnoea as a side effect. The present article is intended to review the current literature regarding dyspnoea occurrence in ACS patients, especially those treated with ticagrelor, and to propose ticagrelor-associated dyspnoea management recommendations based on current knowledge.
No takes yet. Share an insight, caveat, or question.
Parodi et al. (2014) conducted a review in Acute coronary syndrome (ACS). Ticagrelor vs. Clopidogrel or Prasugrel was evaluated. Ticagrelor-related dyspnoea is a common side effect occurring in 10-20% of patients, but it is generally mild and transient, and drug discontinuation should only be considered if it is persistent and intolerable.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: